^
Association details:
| Biomarker: | TARDBP-BRAF fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | plixorafenib (FORE-8394) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses
Excerpt:
Heterogeneous patterns of drug response to RAF and MEK inhibitors of cell lines harboring BRAF fusions compared toBRAFV600E mutant lines...Cell lines with BRAF fusions, except SK-MEL-23, demonstrated resistance to PLX8394, a BRAF inhibitor developed as a “paradox breaker...
DOI:
10.1016/j.celrep.2019.09.009
